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ABSTRACT
Purpose. The primary objective of the studies was to demonstrate bioequivalence between the oral granules
formulation and chewable tablet of montelukast in the fasted state. Effect of food on the pharmacokinetics of the oral
granules was also evaluated.
Methods. The Formulation Biocomparison Study (Study 1) and the Final Market Image Study (Study 2) each used
an open-label, randomized, 3-period crossover design where healthy adult subjects (N = 24 and 30, respectively)
received montelukast as a single 4-mg dose of the oral granules formulation and a 4-mg chewable tablet fasted, and
a single 4-mg dose of the oral granules formulation with food (on 2 teaspoons of applesauce [Study 1] or after
consumption of a high-fat breakfast [Study 2]). The formulations were to be considered bioequivalent if the 90%
conﬁdence intervals (CIs) for geometric mean ratios (GMRs) (oral granules/chewable tablet) for the AUC0-• and Cmax
of montelukast were within the prespeciﬁed comparability bounds of (0.80, 1.25). For the food-effect assessment in
Study 1, comparability bounds were prespeciﬁed as (0.50, 2.00) only for the 90% CI of the GMR (oral granules
fed/oral granules fasted) for the AUC0-• of montelukast; the 90% CI of the GMR for the Cmax of montelukast,
however, also was computed. In Study 2, 90% CIs of the GMRs (oral granules fed/oral granules fasted) for the
AUC0-• and Cmax of montelukast were computed; comparability bounds were not prespeciﬁed.
Results. Comparing the exposure of the formulations, the 90% CIs of the GMRs for AUC0-• and Cmax were within
the prespeciﬁed bound of (0.80, 1.25). For AUC0-•, the GMRs (90% CI) for Study 1 and Study 2 were 1.01 (0.92,
1.11) and 0.95 (0.91, 0.99), respectively. For Cmax, respective values were 0.99 (0.86, 1.13) and 0.92 (0.84, 1.01). When
the oral granules formulation was administered with food, 90% CIs of the GMRs for both AUC0-• and Cmax in both
studies were contained within the interval of (0.50, 2.00).
Conclusions. The 4-mg oral granules and 4-mg chewable tablet formulations of montelukast administered in the
fasted state are bioequivalent. Single 4-mg doses of the oral granules formulation and the chewable tablet of
montelukast are generally well tolerated.
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Introduction
M
ontelukast, a cysteinyl leukotriene type-1
receptor antagonist, is available in age-
appropriate pediatric formulations and is approved
for use in children as young as 6 months old. Pre-
vious studies of the pharmacokinetic proﬁle of
montelukast have demonstrated that the 4-mg oral
granules formulation (in children aged 6 to 24
months) [1], the 4-mg chewable tablet (in children
aged and 2 to 5 years) [2], and a 5-mg chewable
tablet (in children aged 6 to 14 years) provided
37
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ﬁlm-coated tablet, the clinically effective and
approved dose in adults [3].
In this paper, we present pharmacokinetic data
from two studies in healthy adult subjects to
support use of the 4-mg oral granules formulation
of montelukast as an alternate to the 4-mg chew-
able tablet formulation. The aim of both studies
was to demonstrate bioequivalence between the
oral granules and chewable tablet formulations of
montelukast in the fasted state.
Methods
Study Design
The Formulation Biocomparison Study (Study 1,
Merck Protocol 090) and the Final Market Image
Bioequivalence Study (Study 2, Merck Protocol
183) were both open-label, randomized 3-period,
single-dosecrossoverstudiesinwhichhealthyadult
subjects received a single 4-mg dose of the mon-
telukast oral granules formulation fasted, a single
4-mg dose of the montelukast chewable tablet for-
mulation fasted, and a single 4-mg dose of the
montelukast oral granules formulation with food.
During the assessment of the effect of food in the
respective studies, the 4-mg oral granules dose was
administered on 2 teaspoons of applesauce (Study
1) and 5 minutes after consumption of a high-fat
breakfast consisting of 2 fried eggs, 1 slice of but-
teredwhitebreadtoast,2stripsofbacon,240 mLof
whole milk, and 4 ounces hash brown potatoes
(Study 2). Within each study, subjects were allo-
cated to one of six treatment sequences using a
computer-generated randomized allocation sched-
ule. In both studies, each treatment period was
separated by a washout period of at least 96 hours.
Both studies were conducted following regulatory
guidelinesregardingbioequivalenceavailableatthe
time the research was conducted [4–5].
The protocol for Study 1 was reviewed and
approved by Southern Institutional Review Board,
Inc. (Miami, FL), and the study was conducted at
Clinical Pharmacology Associates, Inc., in Miami,
FL between March 26, 1999 and April 21, 1999.
The protocol for Study 2 was reviewed and
approved by Research Consultants Review Com-
mittee (Austin, TX), and the study was conducted
at PPD Development—Research Triangle Park
Clinic in Morrisville, NC between June 3, 2000
and July 7, 2000. All subjects gave written
informed consent before any study procedure was
performed.
Subjects
In both studies, healthy adult men and nonpreg-
nant women between 18 and 45 years of age and
within 20% of ideal weight for age and height were
eligible. Subjects were excluded if they were
current smokers (or former smokers who quit
within 1 year before the ﬁrst study visit), used any
prescription or over-the-counter medications
within 14 days, or used drugs or ingested food with
known activities of inhibiting or inducing cyto-
chrome P-450 metabolism within 30 days of the
ﬁrst study visit. Subjects were also excluded if they
had any history of drug and/or alcohol abuse, or
had any nonconventional dietary habits. Women
agreed not to become pregnant during the study
and to use double-barrier contraception methods
for at least 14 days prior to the ﬁrst study visit
through at least 14 days following the last study
visit.
Procedures
At the discretion of the investigator, subjects were
either admitted to the clinical research unit the
evening prior to each dosing day or in the morning
at least 2 hours prior to the time of dosing. All
subjects fasted for approximately 8 hours, except
for water, before each dose until 2 hours postdose
(Study 1) or 4 hours postdose (Study 2), and
remained in the unit until the 24-hour plasma
sample was obtained.
Sample Collection, Processing, and
Pharmacokinetic Assay
Blood samples for determination of plasma con-
centrations of montelukast were collected in
evacuated blood collection tubes containing
sodium or lithium heparin as the anticoagulant at
the following time points during each dosing
period: predose (0) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8,
10, 12, 16, and 24 hours postdose. Blood was cen-
trifuged immediately and the plasma fraction
transferred to opaque cryotubes that were then
covered with aluminum foil (to protect samples
from exposure to light) and stored at -70°C until
shipment on dry ice to Merck Research Laborato-
ries (West Point, Pennsylvania, USA) for assay.
Plasma concentrations of montelukast were deter-
mined using a high-pressure liquid chromatogra-
phy (HPLC) assay with ﬂuorescence detection [6].
When a calculated concentration was more than
10% higher than the upper limit of quantitation,
the sample was diluted with control plasma and
reanalyzed. The assay has a lower limit of quanti-
38 Knorr et al.
Arch Drug Info 2010;3:37–43tation of 3.0 ng/mL for montelukast; sample con-
centrations calculated more than 15% lower than
3.0 ng/mL (i.e., <2.55 ng/mL) were assigned a
value of 0 ng/mL for estimating the pharmacoki-
netic parameters using noncompartmental
methods.
Pharmacokinetic Methods
The primary pharmacokinetic parameters com-
pared between treatments were the area under the
concentration time curve (AUC) from time = 0t o
inﬁnity (AUC0-•) and maximum plasma concentra-
tion (Cmax). Other pharmacokinetic parameters
evaluated were time to Cmax (Tmax) and apparent
terminal half life (t1/2). Nominal plasma sampling
times were veriﬁed against actual sampling times,
with actual sampling times used for determination
of all pharmacokinetic parameters. The Cmax and
Tmax of montelukast were obtained by visual
inspection of individual plasma concentration-
time proﬁles. The AUC to the last quantiﬁable
time point (AUClast) was calculated using the trap-
ezoidal rule. The terminal elimination rate con-
stant (b) for montelukast was determined for each
individual by log-linear regression of terminal
plasma concentration-time values. The AUC to
the last quantiﬁable time point to inﬁnity
(AUClast-•) was calculated using the concentration
from the last available time point (Clast) divided by
the corresponding b value. AUC0-• represents the
sum of AUClast and AUClast-•. Individual t1/2 values
were determined as t1/2 = ln2/b.
Tolerability Methods
Tolerability was assessed by monitoring for
adverse experiences as well as by evaluation of
physical examination, 12-lead electrocardiogram,
laboratory safety tests (hematology, serum chem-
istry, urinalysis), and vital signs (blood pressure,
heart rate, respiratory rate, oral temperature).
Statistical Methods
Pharmacokinetic parameters were analyzed using
an analysis of variance (anova) model appropriate
for a 3-period, crossover design containing factors
for subject, period, and treatment. Since carryover
effect was found not to be signiﬁcant for any of the
pharmacokinetic parameters, the factor was
removed from the model.
A log transformation was applied to the AUC0-•
and Cmax. In Study 1, the inverse transformation
was applied to the t1/2, and use of the transformed
data generally satisﬁed the assumptions of the
anova model. In Study 2, however, the anova was
applied to the ranks of the t1/2 data (the inverse
transformation was initially applied to t1/2 but
residuals from the anova model failed the Shapiro-
Wilk test for normality).
Following regulatory guidelines regarding
bioequivalence available at the time the research
was conducted [4–5], the formulations were to be
considered bioequivalent if the 90% conﬁdence
intervals (CIs) for geometric mean ratios (GMRs)
(oral granules/chewable tablet) for the AUC0-• and
Cmax of montelukast were within the prespeciﬁed
comparability bounds of (0.80, 1.25). The effect of
food on the oral granules formulation was evalu-
ated by comparing the pharmacokinetics after
administration of the oral granules formulation
with and without food. For the food-effect assess-
ment in Study 1, comparability bounds were pre-
speciﬁed as (0.50, 2.00) only for the 90% CI of the
GMR (oral granules fed/oral granules fasted) for
the AUC0-• of montelukast; the 90% CI of the
GMR for the Cmax of montelukast, however, also
was computed. In Study 2, 90% CIs of the GMRs
(oral granules fed/oral granules fasted) for the
AUC0-• and Cmax of montelukast were computed;
comparability bounds were not prespeciﬁed.
Study 1 had 89% power overall that the 90% CI
for both the AUC0-• and Cmax would be contained
in the prespeciﬁed comparability bounds, assum-
ing a true GMR of 1.0. This was based upon
approximate within-subject standard deviation
estimates (on the log scale) obtained using data
from a previous study: 0.119 (ln ng·hr/mL) and
0.23 (ln ng/mL) for the AUC(0-•) and Cmax of mon-
telukast, respectively. Study 2 had 80% power
overall that the 90% CI for both the AUC0-• and
Cmax would be contained in the prespeciﬁed com-
parability bounds, also assuming a true GMR of
1.0. This was based upon approximate within-
subject standard deviation estimates (on the log
scale) obtained using data from Study 1: 0.187
(ln ng·hr/mL) and 0.289 (ln ng/mL) for the
AUC(0-•) and Cmax of montelukast, respectively, in
the fasted state.
Results
Subject Population
Twenty-four subjects were enrolled in Study 1,
received all 3 doses of study medication, and com-
pleted the study. Subject demographics are in
Table 1. Subjects were predominantly women
(62.5%) and Hispanic (91.7%). Data from all 24
subjects were included in pharmacokinetic analy-
ses and the evaluation of safety.
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2; 30 subjects received all 3 doses of study medi-
cation and completed the study. One subject dis-
continued from the study due to difﬁculty with the
blood sample collection. Subject demographics are
in Table 1. Subjects were predominantly men
(64.5%) and white (71.0%). Data from the 30 sub-
jects who received all 3 doses of montelukast and
completed the study were included in pharmaco-
kinetic analyses. Data from all randomized sub-
jects were included in the evaluation of safety.
Bioequivalence (Fasted State)
The mean (standard deviation [SD])
concentration-time proﬁles for the oral granules
formulation (administered without food) and the
chewable tablet were similar in both studies
(Figures 1 and 2). The 4-mg montelukast oral
granules formulation and the montelukast
chewable tablet met the deﬁnition for bioequiva-
lence: the 90% CI of the GMR (oral granules
formulation/chewable tablet) for both AUC0-•
and Cmax in each study was contained within the
prespeciﬁed interval of (0.80, 1.25) (Table 2). The
median Tmax of montelukast in the fasted state was
observed 2.0 hours after administration of both the
oral granules formulation and the chewable tablet
in both studies (Table 3).
Food Effect
In Study 1, the plasma-concentration-time proﬁles
of montelukast were essentially similar after
administration of the 4-mg oral granules formula-
tion with and without applesauce (Figure 1). The
geometric mean AUC0-• values with and without
applesauce were nearly identical, and the 90% CI
for the GMR (fed/fasted) was well within the
prespeciﬁed interval of (0.50, 2.00) (Table 4).
Although the geometric mean value for the Cmax of
montelukast with applesauce was slightly numeri-
cally lower than without applesauce, the 90% CI
for the GMR was also well within the (0.50, 2.00)
interval. The median Tmax of montelukast was
similar after administration of the oral granules
Table 1 Subject demographics (Study 1 and Study 2)
Study 1 (Formulation
Biocomparison Study)
Study 2
† (Final Market
Image Bioequivalence
Study)
Age (years), mean (range)
Male 32 (24 to 43) 27 (19 to 43)
Female 37 (27 to 44) 30 (21 to 44)
Total 35 (24 to 44) 28 (19 to 44)
Gender, n (%)
Male 9 (37.5) 20 (64.5)
Female 15 (62.5) 11 (35.5)
Race, n (%)
Black 1 (4.2) 6 (19.4)
Hispanic 22 (91.7) 3 (9.7)
White 1 (4.2) 22 (71.0)
Weight (kg), mean (range)
Male 76.1 (61.4 to 89.0) 78.4 (61.5 to 90.5)
Female 64.9 (50.0 to 81.0) 62.0 (51.3 to 79.8)
Total 69.1 (50.0 to 89.0) 72.6 (51.3 to 90.5)
Height (cm), mean (range)
Male 173.2 (163.0 to 183.3) 178.0 (170.2 to 184.2)
Female 170.0 (150.0 to 168.0) 165.0 (158.8 to 175.3)
Total 165.5 (150.0 to 183.3) 173.4 (158.8 to 184.2)
†Includes one subject who was discontinued prior to completion of the study due to difficulty with the blood draws. A total of 31 subjects were randomized and 30
subjects completed the study.
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Figure 1 Mean (SD) montelukast plasma concentration
vs. time after administration of single 4-mg doses of the oral
granules formulation with and without applesauce and the
chewable tablet (Study 1).
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2.0 hours, respectively) (Table 3).
In Study 2, administration of the oral granules
formulation after consumption of a high-fat break-
fast resulted in a decreased and delayed mean peak
concentration compared with administration
without food (Figure 3). The geometric mean
values for AUC0-• with and without food were
similar, and the GMR (fed/fasted) (90% CI) was
1.04 (0.99, 1.09) (Table 4). The GMR (fed/fasted)
for Cmax was 0.64 and the 90% CI was (0.59, 0.71).
The median Tmax of montelukast was delayed after
administration of the oral granules formulation
with a high-fat breakfast compared with the fasted
state (6.00 and 2.00 hours, respectively) (Table 3).
Tolerability
Nineteen subjects reported a total of 38 clinical
adverse experiences, each of which was transient
and self-limited. Of these, 10 clinical adverse expe-
riences in 7 subjects were considered drug related
by the investigator, with headache (N = 6) being
the most frequently reported. One subject experi-
enced transient increased alanine aminotransferase
and increased aspartate aminotransferase, both
considered possibly drug related by the investiga-
tor. There were no serious adverse experiences or
discontinuations from therapy due to an adverse
experience.
Discussion
Bioequivalence between the 4-mg oral granules
and chewable tablet formulations of montelukast
was established by demonstrating that the 90%
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Figure 2 Mean (SD) montelukast plasma concentration
vs. time after administration of a single 4-mg dose of the
oral granules formulation or the chewable tablet of mon-
telukast without food (Fasted) (Study 2).
Table 2 Summary statistics and the GMR (oral granules formulation/chewable tablet formulation) with 90% CIs for
AUC0-• (ng·hr/mL) and Cmax (ng/mL) of montelukast after administration of single 4-mg doses (fasted) (Study 1 and Study 2)
Study 1 (Formulation BC Study) Study 2 (Final Market Image BE Study)
OG Fasted
(N = 24)
CT Fasted
(N = 24)
OG Fasted
(N = 30)
CT Fasted
(N = 30)
AUC0-• (ng·hr/mL)
Geometric mean  SD 1,223.1  342.3 1,208.3  467.4 1,148.5  392.4 1,210.3  412.3
GMR (90% CI) 1.01 (0.92, 1.11) 0.95 (0.91, 0.99)
Cmax (ng/mL)
Geometric mean  SD 198.8  53.8 201.7  91.6 175.4  59.2 190.0  64.3
GMR (90% CI) 0.99 (0.86, 1.13) 0.92 (0.84, 1.01)
BC = biocomparison; BE = bioequivalence; CI = conﬁdence interval; CT = chewable tablet; GMR = Geometric mean ratio (OG formulation/CT formulation);
OG = oral granules; SD = between-subject standard deviation.
Table 3 Summary statistics for Tmax (Hours) after administration of single 4-mg doses of the oral granules formulation of
montelukast with and without food and the chewable tablet without food (Study 1 and Study 2)
Study 1 (Formulation BC Study) Study 2 (Final Market Image BE Study)
OG with
Applesauce
†
(N = 24)
OG Fasted
(N = 24)
CT Fasted
(N = 24)
OG with
High-fat Meal
‡
(N = 30)
OG Fasted
(N = 30)
CT Fasted
(N = 30)
Mean  SD 3.4  1.2 2.1  1.1 2.2  0.8 6.35  2.95 2.28  1.03 2.50  1.05
Median (Range) 3.0 (1.5 to 6.0) 2.0 (1.0 to 6.0) 2.0 (1.0 to 4.0) 6.00 (1.50 to 12.00) 2.00 (1.00 to 6.00) 2.00 (1.00 to 6.00)
†OG administered on 2 teaspoons of applesauce.
‡OG administered 5 minutes after consumption of a high-fat breakfast.
BC = biocomparison; BE = bioequivalence; CT = chewable tablet; OG = oral granules; SD = between-subject standard deviation.
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chewable tablet) for the AUC0-• and Cmax of mon-
telukast were within the prespeciﬁed interval
(0.80, 1.25) when administered in the fasted state
to adult subjects. Determination of bioequivalence
between the 4-mg oral granules and 4-mg chew-
able tablet formulations supports the interchange-
ability of these formulations for use in 2- to
5-year-old patients.
The effect of food on the pharmacokinetics of
the oral granules formulation was also evaluated in
these two studies. In Study 1, administration of a
single 4-mg dose of the oral granules formulation
with applesauce, a food commonly consumed by
young children, had no effect on overall drug
exposure, as indicated by the nearly identical
AUC0-• values observed when the oral granules
formulation was administered with and without
applesauce.
Study 2 evaluated the effect of the oral granules
formulation after consumption of a high-fat break-
fast. Although it is unlikely that a meal with such a
high-fat and calorie content would be consumed
by 6-month- to 2-year-old patients, it is generally
considered compositionally to maximally affect
pharmacokinetics of the drug being evaluated [7].
Although consumption of a high-fat breakfast had
no evident effect on the extent of absorption, as
indicated by the similarity between AUC0-• values
after administration of the oral granules formula-
tion with and without food, the Cmax, however, was
statistically signiﬁcantly lower (36%) and the Tmax
delayed (from 2 to 6 hours) after administration
with a high-fat breakfast. Presumably, the rate of
absorption was slowed due to the longer gastric
emptying time caused by the high-fat content of
the breakfast. This delay in absorption should not
be clinically important for a chronically adminis-
tered drug like montelukast, whose pharmacologic
effects are more dependent on extent of systemic
exposure (i.e., AUC) rather than on maximum
peak plasma concentrations [1–3].
In summary, the 4-mg oral granules and 4-mg
chewable tablet formulations of montelukast are
bioequivalent when administered in the fasted
state, supporting the interchangeability of these
formulations. Single 4-mg doses of the oral gran-
ules and chewable tablet formulations of mon-
telukast are generally well tolerated.
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Table 4 Summary statistics and the GMR (Fed/Fasted) with 90% CIs for AUC0-• (ng·hr/mL) and Cmax (ng/mL) of
montelukast after administration of single 4-mg doses of the oral granules formulation with and without food (Study 1 and
Study 2)
Study 1 (Formulation BC Study) Study 2 (Final Market Image BE Study)
OG with Appelsauce
†
(N = 24)
OG Fasted
(N = 24)
OG with High-fat Meal
‡
(N = 30)
OG Fasted
(N = 30)
AUC0-• (ng·hr/mL)
Geometric mean  SD 1,225.7  528.9 1,223.1  342.3 1,191.8  380.3 1,148.5  392.4
GMR (90% CI) 1.00 (0.92, 1.10) 1.04 (0.99, 1.09)
Cmax (ng/mL)
Geometric mean  SD 182.8  78.2 198.8  53.8 112.8  26.2 175.4  59.2
GMR (90% CI) 0.92 (0.80, 1.06) 0.64 (0.59, 0.71)
†OG administered on 2 teaspoons of applesauce.
‡OG administered 5 minutes after consumption of a high-fat breakfast.
BC = biocomparison; BE = bioequivalence; CI = conﬁdence interval; CT = chewable tablet; GMR = Geometric mean ratio (fed/fasted); OG = oral granules;
SD = between-subject standard deviation.
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Figure 3 Mean (SD) montelukast plasma concentration
vs. time after administration of single 4-mg doses of the oral
granules formulation of montelukast with and without a
high-fat breakfast (Study 2).
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